Gamma scintigraphy is a proven imaging technique used to visualize the in vivo performance of pharmaceutical dosage forms. We have over 25 years’ experience in the design, conduct and reporting of scintigraphic studies, helping customers understand the impact of formulation composition, patient factors and human physiology on clinical outcomes.
Low levels of a gamma-emitting isotope are included in the formulation during product manufacture to allow real-time observation of clinical performance following dosing in human subjects.
Key applications include: oral and inhaled drug delivery.
Oral drug product performance;
Inhaled drug product performance;
Gamma scintigraphy is also used to study the pharmacodynamics of new chemical entities.
Concomitant administration of radiolabelled food or placebo systems with clinical formulations can allow the observation and quantification of pharmacological effects. Examples include:
Gamma scintigraphic assessments can be included with a standard Phase I clinical protocol, and combined with standard safety, pharmacokinetic and pharmacodynamic endpoints.
Statistics, Pharmacokinetics and Scintigraphics:
Our scintigraphic analysts provide expert review and interpretation of scintigraphic data, providing both qualitative and quantitative analysis of drug product performance and pharmacodynamic effects during a study. Quotient has designed, delivered and reported >100 scintigraphy studies across a range of drug products.